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Objectives The purpose of this study was to examine the relationship between changes in pulmonary vascular resistance
(PVR) and right ventricular ejection fraction (RVEF) and survival in patients with pulmonary arterial hypertension
(PAH) under PAH-targeted therapies.
Background Despite the fact that medical therapies reduce PVR, the prognosis of patients with PAH is still poor. The primary
cause of death is right ventricular (RV) failure. One possible explanation for this apparent paradox is the fact
that a reduction in PVR is not automatically followed by an improvement in RV function.
Methods A cohort of 110 patients with incident PAH underwent baseline right heart catheterization, cardiac magnetic res-
onance imaging, and 6-min walk testing. These measurements were repeated in 76 patients after 12 months of
therapy.
Results Two patients underwent lung transplantation, 13 patients died during the first year, and 17 patients died in the
subsequent follow-up of 47 months. Baseline RVEF (hazard ratio [HR]: 0.938; p  0.001) and PVR (HR: 1.001;
p  0.031) were predictors of mortality. During the first 12 months, changes in PVR were moderately correlated
with changes in RVEF (R  0.330; p  0.005). Changes in RVEF (HR: 0.929; p  0.014) were associated with
survival, but changes in PVR (HR: 1.000; p  0.820) were not. In 68% of patients, PVR decreased after medical
therapy. Twenty-five percent of those patients with decreased PVR showed a deterioration of RV function and
had a poor prognosis.
Conclusions After PAH-targeted therapy, RV function can deteriorate despite a reduction in PVR. Loss of RV function is asso-
ciated with a poor outcome, irrespective of any changes in PVR. (J Am Coll Cardiol 2011;58:2511–9) © 2011
by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.06.068m
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c
tPulmonary arterial hypertension (PAH) is a progressive
disease of the pulmonary vasculature leading to increased
pulmonary vascular resistance (PVR), elevated pulmonary
artery pressure, right ventricular (RV) dysfunction, and
ultimately, RV failure and death (1,2). Prognosis is strongly
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Manuscript received May 5, 2011; accepted June 7, 2011.associated with RV parameters, such as cardiac index and
right atrial pressure (3–5). Guided by the premise that RV
failure follows an increased load, the current strategy to
preserve RV function is by attempting to reduce the PVR.
This strategy is effective when loading conditions can be
normalized, which is the case in patients with PAH after
lung transplantation and in patients with chronic thrombo-
See page 2520
embolic pulmonary hypertension after pulmonary endarterectomy
(6–8). Although PVR can be reduced by means of PAH-specific
edication, PVR remains elevated in the vast majority of patients
nd the prognosis remains unsatisfactory (3,9). This apparent
ontrast between hemodynamic success and poor prognosis raises
he question whether RV dysfunction can progress even when the
VR is lowered but not normalized by current medical therapies.
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Progressive Right Heart Dysfunction After Therapy December 6, 2011:2511–9Therefore, the aim of the pres-
ent study was to investigate the
relationship between changes in
PVR and right ventricular ejection
fraction (RVEF) and survival, as
assessed by means of right heart
catheterization (RHC) and cardiac
magnetic resonance (CMR) imag-
ing in a cohort of patients with
PAH receiving PAH-targeted
medical therapy.
Methods
Patients. This study was part of
a prospective ongoing research
program to assess the value of
CMR imaging in patients with
pulmonary hypertension. Be-
tween March 2002 and March
2007, 657 patients were referred
to the VU University Medical
Center, Amsterdam, the Nether-
lands, because of a suspected di-
agnosis of pulmonary hyperten-
sion. Based on World Health
Organization guidelines (10), 179 patients were diagnosed
as having PAH. Inclusion criteria were: 1) patients diag-
nosed with PAH; and 2) RHC, CMR imaging, and 6-min
walk test (6MWT) completed within 2 weeks of diagnosis
and before the initiation of therapy. Exclusion criteria
were: 1) congenital systemic-to-pulmonary shunts (n 
32); and 2) contraindications for CMR imaging (e.g.,
implanted devices, claustrophobia) (n  28).
In total, 119 patients with PAH met the criteria and
were enrolled. Nine patients were excluded because of
incomplete data. Baseline measurements were completed
in 110 patients. Thirteen patients died during the first
year of follow-up. Seven patients did not undergo a
second RHC and were excluded from the follow-up
analysis. Ninety of the 110 patients underwent follow-up
measurements consisting of a second RHC, CMR imag-
ing, and 6MWT after 12 months of PAH-targeted
medical treatment. Six patients were excluded from the
final analysis because the time between the second RHC
and CMR imaging was longer than 1 month. Five
patients were excluded due to incomplete CMR data, and
3 patients were excluded due to insufficient CMR image
quality. Seventy-six patients completed follow-up mea-
surements (Fig. 1). All 110 patients were followed
clinically on a regular basis by outpatient visits and
telephone contacts until May 1, 2010.
Medical treatment comprised prostacyclins, endothelin
receptor antagonists, and phosphodiesterase 5 inhibitors,
either alone or in various combinations. Patients with a
Abbreviation and
Acronyms
CMR  cardiac magnetic
resonance
CO  cardiac output
EDVI  end-diastolic
volume index
ESVI  end-systolic volume
index
PAP  mean pulmonary
artery pressure
PAH  pulmonary arterial
hypertension
PCWP  pulmonary
capillary wedge pressure
PVR  pulmonary vascular
resistance
RHC  right heart
catheterization
RV  right ventricular/
ventricle
RVEF  right ventricular
ejection fraction
6MWT  6-min walk testpositive response to an acute vasodilator challenge weretreated with calcium antagonists (10). All patients received
oral anticoagulants. During follow-up, many patients went
through one or more treatment regimens.
This study was approved by the institutional “Review
Board on Research Involving Human Projects” of the VU
University Medical Center, Amsterdam, the Netherlands.
All participants gave written informed consent.
Right heart catheterization. Hemodynamic assessment
was performed with a 7-F balloon-tipped, flow directed
Swan-Ganz catheter (131HF7, Baxter Healthcare Corp.,
Irvine, California) during continuous electrocardiography
monitoring. PVR was calculated as: (mPAP PCWP)/CO
mPAP is mean pulmonary artery pressure, PCWP is
ulmonary capillary wedge pressure, and CO is cardiac
utput).
-min walk test. The 6MWT was performed according to
merican Thoracic Society guidelines (11).
MR imaging. CMR imaging was performed on a Sie-
ens 1.5-T Sonato scanner (Siemens Medical Solutions,
rlangen, Germany), equipped with a 6-element phased-
rray receiver coil. electrocardiography-gated cine imaging
as performed using a balanced steady-state precession
ulse sequence during repeated breath-holds. Short-axis
mages from base to apex of the ventricles were obtained
ith a typical slice thickness of 5 mm and an interslice gap
Figure 1 Study Profile
*Excluded because of a missing second right heart catheterization (RHC) (n  7),
interval between the second RHC and cardiac magnetic resonance (CMR) imag-
ing 1 month (n  6), incomplete CMR cines (n  5), and insufficient CMR
image quality (n  3). 6MWT  6-min walk test.
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December 6, 2011:2511–9 Progressive Right Heart Dysfunction After Therapyof 5 mm. MR parameters were: temporal resolution be-
tween 35 and 45 ms, typical voxel size 1.5 1.8 5.0 mm3,
ip angle 60°, receiver bandwidth 930 Hz/pixel, field of
iew 280 340 mm2, repetition time/echo time 3.2/1.6 ms,
nd matrix 256  156.
During post-processing, a blinded observer analyzed the
hort-axis images with the MASS software package (MEDIS
edical Imaging Systems, Leiden, the Netherlands). On
nd-diastolic images (first cine after the R-wave trigger) and
nd-systolic images (cine with visually the smallest cavity
rea), endocardial contours of the left ventricle and RV were
btained by manual tracing. Papillary muscles and trabecu-
ae were excluded from the cavity. Ventricular volumes were
stimated using the Simpson rule. Ejection fraction was
alculated as (EDV  ESV)/EDV, where EDV is end-
diastolic volume and ESV is end-systolic volume. Ventric-
ular volumes were indexed by correcting for body surface
area.
Statistical analysis. Data were expressed as mean SD for
ontinuous variables and absolute for categorical variables.
 0.05 was considered significant. Comparisons between
nd within groups were calculated using unpaired and
aired Student t tests. Correlation coefficients were calcu-
ated by the Pearson method. Univariate Cox proportional
azards analyses were applied to test the relationship be-
ween survival and selected demographic, New York Heart
ssociation functional class, distance at 6MWT, and he-
Patient DemographicsTable 1 Patient Demographics
Variable
Total Study
Population
(N  110)
Age, yrs 53 15
Female 84 (76)
Diagnosis
Idiopathic PAH 73 (66)
Familial PAH 7 (6)
Associated PAH
Connective-tissue disease 20 (18)
Portal hypertension 5 (5)
HIV infection 2 (2)
Drugs/toxins 3 (3)
Body surface area, m2 1.8 0.2
NYHA functional class
I/II 53 (48)
III 51 (46)
IV 6 (6)
6MWT
Distance, m 414 135
Medical therapy*
None 2 (2)
Calcium antagonists 3 (3)
Endothelin receptor antagonists 39 (35)
Phosphodiesterase inhibitor 17 (15)
Prostacyclin 15 (14)
Combination therapy 34 (31)Values are mean  SD or n (%). *Refers to the period after baseline measur
HIV  human immunodeficiency virus; NYHA  New York Heart Associatioodynamic and CMR variables measured at baseline.
aplan-Meier survival estimates were stratified by the
ptimal cut-off values of PVR and RVEF and compared by
og-rank tests. The optimal cut-off values were identified
rom receiver-operating characteristic (ROC) curve analyses
y taking the sum of the highest specificity and sensitivity.
ivariate Cox regression analysis was used to test the
elationship between baseline RVEF and PVR and mortal-
ty. Survival was estimated from time of enrollment with
ardiopulmonary death and lung transplantation as the
ndpoints (median period: 59 months [interquartile range
IQR): 30 to 74 months]). Other causes of death were
ensored. We performed a sensitivity analysis to test
hether missing values influenced the results.
The follow-up analysis was performed in 76 patients after
2 months of follow-up. Univariate Cox proportional haz-
rd analyses were performed to analyze the relationship
etween survival and the changes in 6MWT and selected
emodynamic and CMR variables during 1 year of follow-
p. Multivariable Cox survival analyses were used to exam-
ne the independent effect of RVEF and PVR on survival
fter correction for potential confounders. These analyses
ake into account the number of events and the number of
onevents to achieve sufficient power of the test. Based on
aseline RVEF and PVR and the changes in RVEF and
VR during follow-up, a backward multivariable survival
Population Without
Follow-Up
(n  34)
Follow-Up
Population
(n  76) p Value
57 17 50 14 0.023
21 (62) 63 (83) 0.139
19 (56) 54 (71) 0.445
2 (6) 5 (7) 0.834
9 (26) 11 (14) 0.419
3 (9) 2 (3) 0.326
1 (3) 1 (1) 0.542
0 3 (4) 0.550
1.8 0.2 1.9 0.2 0.170
16 (47) 37 (49) 0.222
17 (50) 34 (45) 0.217
1 (3) 5 (7) 0.628
405 170 421 117 0.675
2 (6) 0 0.011
2 (6) 1 (1) 0.966
13 (38) 26 (34) 0.387
7 (21) 10 (13) 0.291
7 (21) 8 (11) 0.251
3 (9) 31 (41) 0.001ements.
n; PAH  pulmonary arterial hypertension; 6MWT  6-min walk test.
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Progressive Right Heart Dysfunction After Therapy December 6, 2011:2511–9analysis was applied to compare the prognostic values of
baseline parameters with those of follow-up parameters.
Patients were considered to have a decreased PVR after a
decrease of at least 15 dyne·s·cm5. In addition, according
to the results of Bradlow et al. (12), a change of 3%
defined an increased RVEF and a value of 3% defined a
decreased RVEF. Patients with decreased PVR were di-
chotomized: decreased PVR  stable/increased RVEF and
decreased PVR  decreased RVEF. A landmark analysis
landmark at month 12) was applied to compare survival
ates of both subgroups. All statistical analyses were carried
ut with SPSS (version 15.0, SPSS, Inc., Chicago, Illinois).
esults
atient characteristics. Table 1 summarizes the demo-
raphics of the study population, and Table 2 shows the
emodynamics and volume measurements. All baseline
easures were obtained in treatment-naive patients with
AH. The mean age of the study population was 53  15
ears, 76% were female, and most patients (66%) were
iagnosed as having idiopathic PAH. The time between
aseline measurements and the end of the study represented
long-term median follow-up period of 59 months (IQR:
0 to 74 months). During that period, 30 patients died from
ardiopulmonary causes and 2 patients underwent lung
ransplantation. Thirteen patients died during the first year,
nd 17 patients died during the median subsequent
ollow-up of 47 months. One patient who died during
ollow-up was treated as a censored case: the cause of death
as given as lung cancer.
Baseline Hemodynamics and Volume MeasuremTable 2 Baseline Hemodynamics and Volu
Variable
Baseline
Population
(N  110)
Hemodynamics
mPAP, mm Hg 49 16
mRAP, mm Hg 7 5
PCWP, mm Hg 7 4
PVR, dyne·s·cm5 745 432
CO, l/min 5.1 1.9
Cardiac index, l/min/m2 2.8 1.0
Heart rate, beats/min 82 14
SvO2, % 66 9
CMR measurements
RVEDVI, ml/m2 71 23
RVESV, ml/m2 47 21
RVEF, % 36 11
LVEDVI, ml/m2 42 14
LVESVI, ml/m2 15 9
LVEF, % 67 10
SVI, ml/m2 28 9
Values are mean  SD.
CMR  cardiac magnetic resonance; CO  cardiac output; LVEDVI 
fraction; LVESV  left ventricular end-systolic volume index; mPAP  m
pulmonary capillary wedge pressure, PVR  pulmonary vascular resis
ventricular ejection fraction; RVESVI  right ventricular end-systolic volume
saturation.aseline survival analyses. Table 3 shows univariate Cox
egression analyses. It was found that both RVEF (hazard
atio [HR]: 0.938; 95% confidence interval [CI]: 0.902 to
.975; p  0.001) and PVR (HR: 1.001; 95% CI: 1.001 to
.002; p 0.031) were associated with survival. In addition,
ge and connective-tissue–disease PAH were associated
ith outcome. Multivariable analyses showed that RVEF
nd PVR remained significantly associated with survival
fter correction for age and type of underlying diagnosis
RVEF: HR: 0.921, 95% CI: 0.884 to 0.959, p  0.001;
VR: HR: 1.001, 95% CI: 1.001 to 1.002, p  0.002).
ROC curve analysis revealed that RVEF and PVR at a
ut-off of 35% and 650 dyne·s·cm5, respectively, were
ndicators of survival (RVEF: area under the ROC curve:
.749, p  0.007; PVR: area under the ROC curve: 0.628,
 0.035). Univariate Cox regression analyses based on
cut-off values showed that low RVEF (HR: 0.237; 95% CI:
0.102 to 0.551; p  0.001) and high PVR (HR: 2.296; 95%
CI: 1.016 to 5.184; p  0.046) were associated with
mortality. Bivariate analysis showed that a low RVEF was
independently associated with poor survival (HR: 0.260;
95% CI: 0.101 to 0.670; p  0.005). Figure 2 shows
Kaplan-Meier survival analyses based on the cut-off values
of PVR and RVEF. Patients with low RVEF (groups 3 and
4) had significantly poorer prognosis compared with pa-
tients with high RVEF (groups 1 and 2), regardless of their
PVR (Fig. 2C). Bivariate Cox regression analysis applied to
the combination of the binary values of RVEF and PVR
showed that the patients with high RVEF/high PVR
(group 2) did not have a different prognosis compared with the
asurements
ulation Without
Follow-Up
(n  34)
Follow-Up
Population
(n  76) p Value
47 17 50 16 0.474
6 5 7 4 0.623
8 4 7 4 0.220
720 513 772 384 0.463
5.2 2.4 4.9 1.3 0.444
2.8 1.3 2.7 0.7 0.325
80 16 85 16 0.313
65 10 66 8 0.727
69 22 72 24 0.611
45 18 48 22 0.709
38 12 35 10 0.160
45 18 41 13 0.268
16 12 14 7 0.364
68 10 66 10 0.323
30 11 27 8 0.133
entricular end-diastolic volume index; LVEF  left ventricular ejection
lmonary artery pressure; mRAP  mean right atrial pressure, PCWP 
RVEDVI  right ventricular end-diastolic volume index; RVEF  rightentse Me
Pop
left v
ean pu
tance,index, SVI  stroke volume index, SvO2  mixed venous oxygen
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atients with low RVEF/low PVR (group 3) had similar
Univariate Cox Regression Analysesof B seline VariablesTable 3 Un variate Cox Regres ion Analysesof Baseline Variables
Variable
Baseline Population
(N  110)
p ValueHazard Ratio 95% CI
Age, yrs 1.027 1.001–1.052 0.040
Sex
Male 1.000
Female 0.789 0.323–1.926 0.603
Diagnosis
Idiopathic PAH 2.064 0.866–4.238 0.163
Familial PAH 0.982 0.862–1.119 0.784
Associated PAH
Connective-tissue disease 0.306 0.143–0.654 0.002
Portal hypertension 0.364 0.086–1.544 0.170
HIV infection 0.876 0.545–1.408 0.585
Drugs/toxins 0.726 0.099–5.342 0.753
6MWT
Distance, m 0.993 0.990–0.997 0.001
Hemodynamics
mPAP, mm Hg 0.998 0.976–1.020 0.850
mRAP, mm Hg 1.048 0.981–1.120 0.167
PCWP, mm Hg 0.986 0.898–1.082 0.761
PVR, dyne·s·cm5 1.001 1.001–1.002 0.031
CO, l/min 0.669 0.483–0.928 0.016
Cardiac index, l/min/m2 0.560 0.323–0.970 0.039
Heart rate, beats/min 1.014 0.989–1.039 0.274
SvO2, % 0.936 0.900–0.972 0.001
CMR measurements
RVEDVI, ml/m2 1.011 0.996–1.024 0.121
RVESVI, ml/m2 1.014 1.001–1.027 0.048
RVEF, % 0.938 0.902–0.975 0.001
LVEDVI, ml/m2 0.962 0.931–0.994 0.019
LVESVI, ml/m2 0.942 0.888–0.998 0.045
LVEF, % 0.998 0.960–1.036 0.900
SVI, ml/m2 0.945 0.899–0.993 0.025
CI  confidence interval; other abbreviations as in Tables 1 and 2.
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Figure 2 Survival Rates of Patients With PAH Stratified Accord
(A) Patients with pulmonary vascular resistance (PVR) 650 dyne·s·cm5 showed
(B) Patients with right ventricular ejection fraction (RVEF) 35% showed better su
(C) Survival rates based on the coupling of PVR and RVEF. PAH  pulmonary arterognosis compared with patients with low RVEF/high PVR
group 4) (p  0.830). In addition, patients of group 3 and
atients of group 4 had 5.2 times greater HRs compared with
igh RVEF/low PVR patients (group 1) (p  0.01).
hanges with follow-up. After a median period of 12
onths (IQR: 10 to 16 months) of PAH-specific medical
reatment, pulmonary pressures remained almost unaltered,
hereas PVR was significantly decreased. In addition,
ardiac index was improved and the 6MWT was stable. No
ther changes in cardiac functional parameters were ob-
erved (Table 4). Furthermore, with respect to the effects of
Differences Between Characteristicsat Baseline and at 12-Month Follow-UpTable 4 Differences Betw en Characteristicsat Baseline and at 12-Month Follow-Up
Variable
Follow-Up Population
(n  76)
P valueBaseline Follow-Up
6MWT
Distance, m 421 117 425 139 0.727
Hemodynamics
mPAP, mm Hg 50 16 47 16 0.176
mRAP, mm Hg 7 4 7 5 0.557
PCWP, mm Hg 7 4 7 4 0.966
PVR, dyne·s·cm5 772 384 660 378 0.003
CO, l/min 4.9 1.3 5.4 2.4 0.032
Cardiac index, l/min/m2 2.7 0.7 3.0 1.2 0.026
Heart rate, beats/min 85 16 83 12 0.182
SvO2, % 66 8 65 10 0.641
CMR measurements
RVEDVI, ml/m2 72 24 76 32 0.099
RVESVI, ml/m2 48 22 51 30 0.167
RVEF, % 35 10 36 13 0.413
LVEDVI, ml/m2 41 13 43 14 0.374
LVESVI, ml/m2 14 7 14 8 0.965
LVEF, % 66 10 67 10 0.267
SVI, ml/m2 27 8 29 8 0.224
Values are mean  SD.
Abbreviations as in Tables 1 and 2.
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p < 0.001
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4. RVEF < 35, PVR > 650 (n = 41)
1.
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3. 4.
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C
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r survival rates than patients with PVR 650 dyne·s·cm5 (p  0.04).
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Progressive Right Heart Dysfunction After Therapy December 6, 2011:2511–9the different classes of drugs, we found no significant
differences between groups (Table 5).
Follow-up survival analyses. Changes in PVR correlated
moderately with changes in RVEF (R  0.330; p  0.005)
(Fig. 3). PVR decreased in both survivors (121  297
dyne·s·cm5) and nonsurvivors (132  432 dyne·s·cm5)
(p  0.927). Changes in RVEF differed significantly be-
tween survivors (3%  9%) and nonsurvivors (5% 
6%) (p  0.001) (Fig. 4). Similar results were found for the
relative changes in PVR (survivors 13%, nonsurvivors
11%; p  0.765) and relative changes in RVEF (survivors
10%, nonsurvivors 20%; p  0.001). Changes in PVR
were not associated with outcome (HR: 1.000; 95% CI:
0.998 to 1.001; p  0.820), whereas changes in RVEF were
independently related to mortality (HR: 0.929; 95% CI:
0.875 to 0.985; p  0.014). Table 6 shows univariate
nalyses of changes in hemodynamic and CMR variables
uring follow-up. After correction for age and connective-
issue–disease PAH, changes in RVEF remained signifi-
antly associated with survival (HR: 0.928; 95% CI: 0.870
o 0.991; p  0.026).
A backward multivariable survival analysis based on
aseline RVEF and PVR and the changes in RVEF and
VR showed that baseline RVEF and the changes in RVEF
uring follow-up had similar prognostic value (baseline
Differences Between Different Classes of Medical Therapies (n  7Table 5 Differences Between Different Classes of Medical Ther
Variable*
Endothelin Receptor Antagonists
(n  26)
Phosp
Changes in PVR, dyne·s·cm5 133 315
Changes in RVEF, % 1 8
Values are mean  SD. *One patient was treated with calcium antagonists and was not included
Abbreviations as in Table 2.
-1000 -500 500 1000
-20
20
40 Survivors
Non-survivors
Changes in PVR
dyne•s•cm
Changes in 
RVEF %
0
0
R = 0.330
-5
Figure 3 Relation Between Changes
in PVR and Changes in RVEF
Changes in PVR were moderately correlated with changes in RVEF
(R  0.330; p  0.005). Abbreviations as in Figure 2.pVEF: HR: 0.926, 95% CI: 0.876 to 0.978, p  0.006;
hanges in RVEF: HR: 0.909, 95% CI: 0.846 to 0.976, p
.009).
In total, 52 patients (68%) showed a significant decrease
n PVR after therapy and were included in the landmark
nalysis. In this group, patients with a decreased RVEF had
ignificantly poorer survival than patients with stable/
ncreased RVEF (p  0.001) (Fig. 5). Both groups had a
imilar decrease in PVR (mean 284  248 dyne·s·cm5;
ifference in PVR p  0.437). We observed no differences
n the baseline characteristics that could account for a
ifferent RV response to a similar decrease in PVR (Online
able A1). Online Table A2 shows the characteristics of
oth groups after follow-up.
Thirteen patients did not survive the first year and
herefore did not undergo follow-up measurements. The
onsurvivors without follow-up measurements showed sim-
lar characteristics to the 17 nonsurvivors with follow-up
easurements (Online Table A3).
iscussion
ur study shows that in a large group of World Health
rganization group 1 patients with PAH on PAH-targeted
herapies, RVEF measured at baseline was a better predictor
f mortality than PVR. Changes in RVEF after 12 months
redicted long-term outcome, whereas changes in PVR did
ot. In addition, we found that changes in PVR were
oderately related to changes in RVEF and that after
edical therapy, RV dysfunction could progress despite a
ecrease in PVR.
ignificance of baseline parameters. In accordance with
revious studies, we showed that RVEF as assessed by
MR imaging had a strong prognostic value (13,14). Kawut
t al. (15) showed that RVEF was an independent predictor
f long-term outcome. In correspondence with earlier stud-
es, we found that baseline PVR was a prognostic predictor
3,4). However, we showed that although a high PVR at
aseline was associated with outcome, the prognosis was
rimarily determined by RVEF. Previously, Ghio et al. (16)
ound similar results in patients with pulmonary hyperten-
ion secondary to left heart disease.
ffects of medical therapies. Thus far, only a few studies
ave studied the therapeutic effects on changes in PVR and
V function. It was previously shown by Roeleveld et al.
17) that epoprostenol therapy lowered PVR but did not
ffect RV dilation and hypertrophy. Chin et al. (18) re-
(n  76)
sterase Inhibitors
 10)
Prostacyclins
(n  8)
Combination Therapy
(n  31) p Value
3 271 95 201 180 271 0.311
1 6 3 10 2 9 0.360
analysis.6)apies
hodie
(n
3
orted that although bosentan reduced PVR, it did not
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that RV mass decreased after sildenafil treatment and
remained stable after bosentan therapy. A randomized
clinical trial by Galie et al. (20) showed that bosentan
treatment was associated with improvement in RV systolic
function as assessed by the RV Doppler index. The last 2
studies cited did not include hemodynamic measures in the
analyses. Although the former studies analyzed treatment
effects in patients with PAH, the relationship between
changes in load and RV function was not been quantified.
The majority of patients in our cohort (68%) had reduced
PVR after medical treatment. However, the reduction in
PVR was modest (12%) and mPAP remained almost
Changes in PVR
D
yn
e.
s.
cm
.
Survivors Non-survivors
-1500
-1000
-500
0
500
1000
p = 0.927
-5
A
Figure 4 Changes in PVR and RVEF After 12 Months of Follow
(A) Changes in PVR did not differ between survivors (blue) and nonsurvivors (red)
whereas nonsurvivors (red) showed decreased RVEF during follow-up. Abbreviation
Univariate Survival Analysesof Chang s in Follow-Up VariablesTable 6 Un riate Survival Analysesof Changes in Follow-Up Variables
Variable
Follow-Up Population
(n  76)
p ValueHazard Ratio 95% CI
Changes in 6MWT
Distance, m 0.996 0.989–1.003 0.239
Changes in hemodynamics
mPAP, mm Hg 1.013 0.975–1.053 0.504
mRAP, mm Hg 1.050 0.945–1.167 0.360
PCWP, mm Hg 1.027 0.944–1.118 0.530
PVR, dyne·s·cm5 1.000 0.998–1.001 0.820
CO, l/min 0.811 0.619–1.062 0.128
Cardiac index, l/min/m2 0.705 0.443–1.123 0.141
Heart rate, beats/min 0.986 0.950–1.024 0.475
SvO2, % 0.965 0.911–1.096 0.314
Changes in CMR measurements
RVEDVI, ml/m2 1.029 1.013–1.045 0.001
RVESVI, ml/m2 1.036 1.018–1.053 0.001
RVEF, % 0.929 0.875–0.985 0.014
LVEDVI, ml/m2 0.928 0.937–1.014 0.179
LVESVI, ml/m2 0.971 0.909–1.037 0.377
LVEF, % 0.988 0.947–1.031 0.576
SVI, ml/m2 0.928 0.843–1.015 0.110Abbreviations as in Tables 1, 2, and 3.unaltered (5%). Despite the small patient groups, we
found nonheterogeneity in the effects among different
classes of medical treatment. These results are in correspon-
dence with meta-analyses of randomized controlled trials
showing moderate reductions in PVR and only small
reductions in mPAP over an average study duration of 14
weeks (9). Furthermore, our results agreed with the
findings of previous studies reporting lowered PVR
(ranging from 11% to 39%) after a long-term treat-
ment period (21–26).
Significance of follow-up parameters. Our results on
PVR showed that although this parameter measured at
baseline was of prognostic significance, a change over time
of this parameter was not. However, we cannot conclude
from this result that a change in PVR is not important. It
was found in an earlier study that PVR reduction will lead
to an improvement in survival only if reduced to more than
30% (25). Because this was the case in a minority of our
patients, no conclusions can be made whether a larger
Changes in RVEF
%
Survivors Non-survivors
-20
0
20
40
p <0.001
ccording to Survival
urvivors (blue) showed increased RVEF,
n Figure 2.
Figure 5 Landmark Analysis
Landmark analysis at month 12 of 52 patients with decreased PVR after ther-
apy. Patients with stable/increased RVEF (n  39) had better survival rates
than patients with decreased RVEF (n  13) (p  0.001). Abbreviations as in
Figure 2.B
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study.
In the present study, we showed that the changes in
RVEF during follow-up had similar prognostic value in
comparison with baseline RVEF. In addition, a previous
study of our group found that the changes in stroke volume
index and RV and left ventricular volumes were associated
with mortality (13). The results of both studies suggest that
follow-up parameters may provide important prognostic
insights.
The paradox of progressive RV dysfunction despite
decreased PVR. We found that the changes in RVEF were
moderately correlated to the changes in PVR. The most
important finding of this study was that in 25% of the
patients with reduced PVR, RV function deteriorated fur-
ther after follow-up. We showed that the group with
deteriorating RV function had a poor outcome. This dete-
rioration was not explained by the PVR because the reduc-
tion in PVR occurred to a similar extent in patients with
improving and deteriorating RVEF.
RV load consists of peripheral resistance, arterial compli-
ance and characteristic impedance of the proximal pulmo-
nary artery. In previous studies of our group (27,28), it was
shown that resistance and compliance are inversely related
(resistance  constant  1/compliance). As a consequence,
ompliance is strongly correlated to PVR ( peripheral
esistance characteristic impedance), and therefore, we do
ot think that compliance can explain additional variance in
elation to RVEF. Recently, we showed that RV total power
associated with total load [i.e., compliance and PVR]) and
ean power (associated with nonpulsatile load [i.e., PVR])
re proportional (29). These findings emphasized that PVR
s a valid reflection of the load on the RV.
The moderate correlation between PVR and RVEF
ndicated that RV function does not fully adapt to changes
n vascular properties, as is expected in healthy individuals
ue to “coupling” of the heart and arterial functions.
herefore, we expected that other factors play an important
ole in the changes in RVEF over time. Kawut et al. (30)
howed that older age, male sex, and higher level of von
illebrand factor were associated with lower RVEF. We
peculate that genetic differences in RV adaptation to
ressure overload (2) and possible direct effects of current
AH treatments on the heart are responsible for different
V responses. In addition, we hypothesize that the deteri-
ration in RV function might possibly be explained by an
mportant physiological principle: ventricular wall tension.
he current results showed that despite a reduction in PVR,
ulmonary pressures were unaltered after medical treatment;
onsequently, ventricular wall tension will remain un-
hanged (31). If wall tension is the driving force for the RV
o fail, therapies will not prevent the failure if failing
onditions were already present at baseline.
mplications. Here we showed that changes in PVR as
ccomplished by currently available therapies do not prevent
V deterioration in 25% of the patients. Therefore, becauseV function is the primary determinant of prognosis, it is
mportant to analyze the factors that predict RV
ysfunction.
It has been shown that larger reductions in PVR and
PAP (e.g., after lung transplantation or endarterectomy)
an result in improved RV function. We therefore consider
hat a medical treatment strategy that is more effective at
nset could have a more pronounced effect on patient
utcome. Furthermore, understanding the pathways that un-
erlie RV failure could lead to the development of strategies
hat are directly targeted at improving RV function.
tudy limitations. A limitation of this study is that RHC
nd CMR measurements could not be obtained simultane-
usly, which may have potentially resulted in measurements
n different hemodynamic states. However, the median time
etween CMR imaging and RHC was 2 days; therefore, it
as unlikely that the delay affected our conclusions.
In addition, because our study required follow-up mea-
urements, patients who died between baseline and
ollow-up measurements could not be included in the
ollow-up analyses (immortal time bias) (32). However, we
bserved no differences in baseline characteristics between
he nonsurvivors without follow-up measurements and the
onsurvivors with follow-up measurements.
onclusions
n PAH, baseline RVEF was a stronger prognostic predic-
or than baseline PVR. Changes in PVR after follow-up
ere moderately correlated with changes in RVEF. More-
ver, this study showed that in the presence of PAH, right
eart dysfunction may progress despite a reduced PVR by
AH-targeted medical therapies. A deterioration of RV
unction was associated with poor outcome, irrespective of
ny changes in PVR.
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